SomaLogic Accelerating drug discovery and development with
Finding and validating drug targets. Translating biomarkers from preclinical models to human studies. Understanding which patients will benefit from new drugs.
Resistance and prognosis; Prediction and monitoring.
IL-17 antibody; Safety and early efficacy Phase 2a IPF.
Discover how our technology works. Download Document.
S-1-P antagonist, SAD study Phase 1b Oncology ALK inhibitor; PK/PD Phase 2a Psoriasis.
SomaLogic's SOMAscan assay and SOMAmer reagents help our partners succeed by empowering them to characterize biology and pharmacology at a much deeper level. We can now measure thousands of proteins for unbiased discovery or only a few proteins in post-discovery, helping you to choose the right target, the right compound, and the right patients. Our technology uniquely accelerates successful drug discovery and development across the pipeline, from preclinical target discovery to post-market surveillance and companion diagnostics. Phase 1b Oncology.
Anti-angiogenic biotherapeutic; PK/PD study Phase 1b MS.
Breakthrough proteomics tools for the life sciences research community.
Learn more about SomaLogic, our people, our mission, and how to contact us.
Adoptive cell therapy; Safety and host response Phase 4 Oncology.
Finding and validating drug targets. Translating biomarkers from preclinical models to human studies. Understanding which patients will benefit from new drugs. Tracking individual patient responses to drugs in real time. Designing meaningful clinical trials. These are some of the most challenging – and costly – bottlenecks in modern drug discovery and development, and are often behind the failure of promising new compounds.
NSCLC vaccine; Safety and host response Phase 2a IBD.
News, publications, presentations, webinars, technical papers, and inlectual property information.
Finally, many individual SOMAmer reagents may be considered potential therapeutic molecules in their own right.
A revolutionary proteomics platform with multiple applications.
Chemokine ligand antagonist; Safety and early efficacy Phase 2a Oncology.